Nov. 5, 2009 (Business Wire) -- Levi & Korsinsky is investigating the Board of Directors of IMS Health Inc. (“IMS” or the “Company”) (NYSE: RX) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to private equity firm TPG and the CPP Investment Board of Toronto ("CPP"). Under the terms of the agreement, IMS shareholders will receive $22 in cash for each IMS share they own for a total transaction value of approximately $4 billion, including the assumption of debt.

The investigation concerns whether the IMS Board of Directors have breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether TPG and CPP are underpaying for IMS shares, thus unlawfully harming IMS stockholders.

If you own common stock in IMS and wish to obtain additional information, please contact us at the number listed below or visit http://www.zlk.com/ims1.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.